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Themechanisms bywhich estradiol exerts specific actions on
neural function are unclear. In brain the actions of estrogen
receptor (ER)  are well documented, whereas the functions
of ER are not yet fully elucidated. Here, we report that ER
inhibits the activity of ER in an anatomically specific man-
ner within the neonatal (postnatal d 7) brain. Using selective
agonists we demonstrate that the selective activation of ER
in the relative absence of ER activation induces progester-
one receptor expression to a greater extent than estradiol
alone in theventromedial nucleus, butnot themedial preoptic
nucleus, despite high ER expression. Selective activation of
ER attenuates the ER-mediated increase in progesterone
receptor expression in the ventromedial nucleus but has no
effect in medial preoptic nucleus. These results suggest that
ER/ER interactionsmay regulate the effects of estrogens on
neural development and reveal the neonatal brain as a unique
model in which to study the specificity of steroid-induced
gene expression. (Endocrinology 149: 4615–4621, 2008)
STEROIDHORMONE RECEPTORS, as nuclear transcrip-tion factors, exert powerful effects on a broad range of
neural functions (1, 2). Estradiol, although best known for its
role in neuroendocrine function and reproductive behaviors
in rodents (for review, see Ref. 1), has recently been associ-
ated with a number of neurological disorders, including Par-
kinson’s disease (3), Alzheimer’s disease (3), and stroke (4).
Estrogens and selective estrogen receptor modulators
(SERMs) are commonly used clinically, despite a poor un-
derstanding of how these treatments might influence brain
function (5, 6). A growing literature clearly demonstrates that
the actions of estradiol are tissue specific and developmen-
tally dependent, creating the possibility for unwanted and
potentially dangerous side effects of estrogen treatment (7,
8). Therefore, it becomes essential to elucidate the mecha-
nisms by which estradiol and estrogen receptors (ERs) exert
their specific actions within the brain.
To date, two nuclear ERs, ER and ER, have been iden-
tified (9). These two receptors share a highly conservedDNA
binding domain but poor to moderate homology in their
N-terminal domain (containing AF-1) and ligand binding
domain (containing AF-2). Despite the moderate homology
at the ligand binding domain, both ER and ER bind to
estradiol with a similar affinity (9). However, due to differ-
ences in the AF-1 and AF-2 domains, the intracellular actions
of ER and ER may differ significantly (10). ER and ER
are expressed at high levels within specific brain regions and
are often colocalized within cells (11–15). Although a role for
ER in a variety of neural and behavioral functions has been
well documented (for review, see Ref. 1), a clear and direct
function of ER at the cellular level in brain has remained
elusive (for review, see Ref. 16). In contrast, in vitro studies
consistently reveal an inhibitory action of ER on ER tran-
scriptional activity when coexpressed in the same cells (17–
19). Such an interaction between ER and ER has not been
demonstrated at the cellular level in vivo, within developing
brain. Although several reports have demonstrated a role for
ER activity in behavioral outcomes (16, 20–22), the cellular
mechanisms underlying the actions of ER on ER activity
have yet to be demonstrated in vivo.
Within specific regions of the brain, a highly robust bio-
assay for ER activity is the induction of progesterone re-
ceptor (PR) gene expression (14, 23–27). In adult female rats,
estradiol dramatically increases PR within both the medial
preoptic nucleus (MPN) and the ventromedial nucleus
(VMN) of the hypothalamus. However, previous studies
from our laboratory demonstrate that the regulation of PR
expression by estradiol is anatomically and developmentally
specific (25). For example, in neonatal females, estradiol in-
creases PR levels in the MPN at least 50-fold but does not
significantly alter PR levels in the VMN of the same animals.
PR expression within the VMN becomes increasingly more
responsive to estradiol as development ensues. ER protein
is expressed at high levels throughout development in both
regions (28, 29), suggesting that ER activity is transiently
inhibited in the VMN, but not the MPN, during development.
Interestingly, ER expression is high in the neonatal fe-
male VMN but is relativity low in the MPN (13, 28). In
addition, ER expression in the VMN gradually decreases as
First Published Online May 29, 2008
Abbreviations: DMSO,Dimethyl sulfoxide; DPN, diarylpropionitrile;
EB, estradiol benzoate; ER, estrogen receptor; ir, immunoreactivity; KO,
knockout; MPN, medial preoptic nucleus; PB, phosphate buffer; P5,
postnatal d 5; P6, postnatal d 6; P7, postnatal d 7; PPT, 1,3,5 Tris
(4-hydroxyphenyl)-4-propyl-1H-pyrazole; PR, progesterone receptor;
SERM, selective estrogen receptor modulator; TBS, Tris-buffered saline;
VMN, ventromedial nucleus; VMNvl, ventrolateral ventromedial
nucleus.
Endocrinology is publishedmonthly by The Endocrine Society (http://
www.endo-society.org), the foremost professional society serving the
endocrine community.
0013-7227/08/$15.00/0 Endocrinology 149(9):4615–4621
Printed in U.S.A. Copyright © 2008 by The Endocrine Society
doi: 10.1210/en.2008-0511
4615
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 27 October 2014. at 10:12 For personal use only. No other uses without permission. . All rights reserved.
the animal ages. These findings, together with in vitro studies
implicating ER in the inhibition of ER, suggest that ER
functionmay be responsible for the reduced sensitivity of the
VMN to estradiol during development. To test this hypoth-
esis, the actions of the ER subtypeswere dissociatedusing the
in vivo administration of ER and ER selective agonists.
Results suggest that activation of ER inhibits the ER de-
pendent induction of PR expression within the developing
brain in a regionally specific manner. These results implicate
ER in the specificity of estrogen signaling in vivo and, more
specifically, in the proper development of steroid-sensitive
brain areas. In addition, these findings introduce the neo-
natal female VMN as a unique biologically relevant model in
which to examine themechanisms underlying the regulation
and specificity of steroid-induced gene expression.
Materials and Methods
Animals
Subjects were offspring of timed pregnant female Sprague Dawley
rats (60–80 d of age; Taconic Laboratories, Germantown, NY). Animals
were housed on a 14-h light, 10-h dark cycle at a constant temperature
of 25  2 C, with food and water available ad libitum. All females were
allowed to deliver their pups normally. All animal procedures used in
this study were approved by the Institutional Animal Care and Use
Committee at the State University of New York at Albany.
All animals were treated on postnatal d 5 and 6 (P5 and P6, respec-
tively), and tissue was collected on postnatal d 7 (P7). All treatment
groups were assigned to at least three different litters to control for litter
effects. In addition, all animals were housed in a mixed sex litter until
tissue was collected. The time period for tissue collection was chosen
based on previous studies demonstrating that a single dosage of estra-
diol benzoate (EB) at this age does not induce PRwithin 48 h in the VMN
but strongly induces PR within the MPN (25).
Treatments
Experiment 1: selective ER-mediated transactivation of PR gene in the brain.
On P5 and P6, female pups received either EB (20 g/kg, n  8), the
ER-selective agonist, 1,3,5 Tris(4-hydroxyphenyl)-4-propyl-1H-pyra-
zole (PPT) (1, 2, or 3 mg/kg sc, n  9, 10, 12), or an equal volume of the
vehicle [0.01 cc/g 10% dimethyl sulfoxide (DMSO) in sesame oil, sc, n
10]. PPT selectively binds to ER with a 400-fold preference over ER
and has been a potent activator of ER transcriptional activity, but not
ER, in transfected cell lines (30, 31). The range of PPT dosages was
based on previous studies reporting that PPT in the range of 1–3 mg/kg
can induce PR within the rodent brain similarly to 17-estradiol during
neonatal life (24).
Experiment 2: selective activation of ER and ER. On P5 and P6, female
pups received either EB (20 g/kg, n  8), PPT (2 mg/kg, n  8) alone,
or PPT in combinationwith the ER selective agonist diarylpropionitrile
(DPN) (0.5, 3.5, or 5 mg/kg, n  10, 9, 7), or an equal volume of the
vehicle (0.01 cc/g 10% DMSO in sesame oil, n 11). DPN demonstrates
a 40-fold higher binding preference for ER and has been 30-fold more
potent in activating transcription using multiple reporter genes in vitro
(31, 32). The dosages of DPN were chosen from previously published
studies in which DPNwas used to manipulate ER activity in the brains
of rodents (24, 33, 34). A range of dosages has been used previously (32)
to study the role of ER in many different behavioral paradigms.
Due to the variability of dosages, we chose to use a broad range of
dosages to find the most effective level of this selective agonist.
Experiment 3: selective activation of ER alone. On P5 and P6, female pups
received the most effective dosage of DPN from experiment 2 (3.5 mg/
kg) or an equal volume of the vehicle (0.01 cc/g 10% DMSO in sesame
oil). A total of 3.5mg/kgDPNprovided the strongest attenuation of PPT
when compared with 0.5 and 5 mg/kg, and was therefore used within
this experiment. Tissue collection and immunocytochemistry were per-
formed as below.
Experiment 4: localization of ER, ER, and PR via immunocytochemistry. P7
females were allowed to reach P7 with no drug treatments. Brains were
collected for ER, ER, and PR via immunocytochemistry as described
below.
Tissue collection
For all experiments animals were anesthetized by hypothermia and
killed by rapid decapitation on P7. Brains were removed from the skull
and quickly immersion fixed in 5% acrolein in 0.1 m phosphate buffer
(PB) (pH 7.6) for 6 h, cryoprotected in 30% sucrose in 0.1 m PB, and cut
at 50 m in the coronal plane. Sections were stored in cryoprotectant
(30% sucrose, 0.1% polyvinyl-pyrrolidone-40 in ethylene glycol and 0.1
m PB) at 20 C until processing for immunocytochemistry.
For experiment 4, animals processed for ER immunocytochemistry
were fixed as described previously using a 3% acrolein in 0.1 m PB
solution for 6 h.
Immunocytochemistry
Immunocytochemistry was performed, as previously described (35,
36), on free floating sections using a rabbit polyclonal antiserum (Dako
Corp. Inc., Glostrup, Denmark) directed against the DNA binding do-
main of the human PR. This antibody detects both the A and B isoform
of PR, and its specificity has been well documented (14, 35). All incu-
bations were performed at room temperature unless otherwise stated.
Sections were rinsed in Tris-buffered saline (TBS) (pH 7.6) (3  5 min),
incubated in 1% sodium borohydride in TBS (10min), rinsed in TBS (4
5 min), incubated in TBS containing 20% normal goat serum, 1% H2O2,
and 1% BSA for 30 min. PR antiserum was diluted 1:1000 in TBS con-
taining 0.3% Triton X-100, 2% normal goat serum (referred to as TTG)
for 72 h at 4 C. Sections were rinsed in TTG (3  5 min), incubated in
biotinylated goat antirabbit IgG (Vector Laboratories, Burlingame, CA)
at a concentration of 5 g/ml in TTG for 90 min. Sections were rinsed
in TTG (2  5 min), in TBS (2  5 min), then incubated in avidin-biotin
complex reagent (Vectastain Elite Kit; Vector Laboratories) for 60 min.
Sections were rinsed in TBS (3  5 min), then incubated in TBS con-
taining 0.05% diaminobenzidine, 0.75 mm nickel ammonium sulfate,
0.15% -d-glucose, 0.04% ammonium chloride, and 0.2% glucose oxi-
dase for approximately 15 min. Sections were rinsed in TBS (3 5 min),
mounted on gelatin-coated slides and coverslipped with Permount
(Fisher Scientific, Pittsburgh, PA).
In experiment 4, immunocytochemistry was performed as described
previously with the following changes: ER was detected using poly-
clonal antisera (C1355; Upstate Signaling, Lake Placid, NY) directed
against the last 15 amino acids in the rat ER for 48 h at 1:2000.
ER immunoreactivity (ir) was detected using mouse monoclonal
human ER (hER) antibody (hERNT-221.3; Ligand Pharmaceuticals,
Inc., San Diego, CA) raised against a synthetic peptide corresponding to
the 14-amino acid N-terminal sequence of hER (1–485 form) at a di-
lution of 1 g/ml. The specificity of this antibody has been previously
published (14). After primary incubation for 72 h, tissue was incubated
in a biotinylated goat antimouse IgG (Vector Laboratories) at a concen-
tration of 4 g/ml in TTG.
Analysis
For both experiments a representative, anatomically matched section
through the rostral MPN and caudal VMN of each animal was selected
for image analysis by an experimenter blind to the treatment group.
Animals from which an anatomical match could not be found due to
damaged sections were excluded from analysis. Microscope images of
the PR-ir in the MPN and ventrolateral VMN (VMNvl) were captured
with aNikonEclipse E600microscope (NikonCorp., Tokyo, Japan) fitted
with a SPOT Insight camera (Diagnostic Instruments, Sterling Heights,
MI) connected to a Dell Inspiron 8600 laptop (Dell Computer Corp.,
Round Rock, TX). National Institutes of Health Image software
(W. Rasband, National Institutes of Health, Bethesda, MD) was used to
analyze captured images. Briefly, the relative total amount of PR-ir
above background levels was determined according to previously pub-
lished methods (37–39). Only cells that had a gray level darker than a
defined criteria above background were counted. The relative amount
of PR-ir in the MPN and VMNvl was determined by measuring the area
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(m2) covered by “thresholded” pixels [i.e. those pixels with a gray level
higher than a defined “threshold” density (specific immunoreactive
staining)]. “Threshold” was determined as a constant function over and
above background OD (i.e. gray level), and was defined as the OD three
times the sd higher than the mean background density. The mean
background density was measured in a region devoid of PR-ir, imme-
diately lateral to the analyzed region containing PR-ir. For experiments
1 and 2, statistical analyses were performed using a one-way ANOVA
(P  0.05), followed by preplanned, pairwise comparisons using
Student-Newman-Keuls post hoc analysis (P  0.05). For experiment 3,
statistical analysis was performed using a Student’s t test (P  0.05).
Results
Experiment 1: selective activation of ER in the relative
absence of ER activation
In the VMN the selective activation of ER alone induced
PR over and above EB treatment. In addition, PPT (2 mg/kg)
induced PR above that of vehicle controls. In contrast, in the
MPN, both EB and all doses of PPT dramatically increased
PR levels above that of vehicle controls.
In the neonatal VMN, one-way ANOVA revealed a main
effect of treatment [F(4,48) 7.674; P 0.001; Fig. 1A]. Post hoc
analysis revealed that PR-ir levels were significantly higher
in the PPT group (2 mg/kg) compared with EB treatment
(P  0.05). In addition, PPT at 2 and 3 mg/kg increased PR
levels compared with oil-treated controls (P  0.001),
whereas EB treatment did not significantly alter PR levels
compared with controls (P  0.072).
In theMPN, one-way ANOVA revealed a significant main
effect of treatment [F(4,51)  13.271; P  0.001; Fig. 1B].
Post hoc analysis revealed that EB and PPT at all doses sig-
nificantly increased PR-ir levels compared with vehicle-
treated controls (P 0.001). EB and PPT treatments were not
different from one another.
Experiment 2: selective activation of ER and ER
Consistent with experiment 1, PPT induced PR levels in
the VMN significantly greater than EB treatment. Further-
more, the effect of PPT was attenuated with the addition of
the ER agonist, DPN. The combination of PPT and DPN
significantly decreased PR levels compared with PPT alone
but were similar to those of EB treatment.
In the VMN, one-way ANOVA revealed a main effect of
treatment [F(5,52)  25.483; P  0.001; Fig. 2A]. Post hoc anal-
ysis revealed that levels of PR-irwere higher in the EB treated
group compared with the oil-treated group (P  0.05). PPT
significantly increased PR levels over and above that of EB
(P  0.001). Furthermore, the effect of PPT was significantly
attenuated by the addition of DPN. All three doses of DPN
in combinationwith PPT decreased PR levels comparedwith
PPT alone (P 0.001 for 3.5 mg/kg, and P 0.05 for 0.5 and
5 mg/kg DPN). In contrast, in the MPN, all treatments sig-
nificantly increased PR levels compared with vehicle con-
trols, but there were no differences between the treatment
groups. One-way ANOVA revealed a significant main effect
of treatment [F(5,56)  22.277; P  0.001; Fig. 2B]. Post hoc
analysis revealed that all treatments (EB, PPT, and PPT plus
DPN) significantly increased PR levels compared with ve-
hicle treatment (P  0.001). PR levels did not differ between
the PPT plus DPN treated groups and the EB treated group.
Experiment 3: selective activation of ER alone
Selective activation of ER alone had no effect on PR-ir
levels in the MPN, suggesting that DPN, at the dose used,
had little effect on ER activity. DPN alone increased PR-ir
levels slightly in the VMN (P 0.05; Fig. 3A). PR-ir levels did
not significantly differ between the DPN treated group and
vehicle-treated group in the MPN (Fig. 3B).
Experiment 4: ER, ER, and PR expression in the
neonatal female VMN and MPN
ER, ER, and PR are all expressed at high levels within
the VMNvl of P7 females (Fig. 4A). Furthermore, the an-
atomical distribution of immunoreactive nuclei fall within
the same region of the VMNvl, suggesting that these three
receptors overlap in their expression within the VMN.



















































FIG. 1. Selective activation of ER, in the relative absence of ER
activation, induces PR expression over and above estradiol in the
VMN, but not the MPN. The mean (SEM) total amount of PR-ir within
the VMNvl or the MPN of female rats on P7 treated with vehicle (n
10), EB (20 g/kg, n  8), or the ER selective agonist, PPT, at 1, 2,
or 3 mg/kg (n  9, 10, 12) on P5 and P6. A, VMNvl. PR-ir levels were
significantly higher after PPT treatment (2mg/kg) compared with EB
treatment. PPT (2 and 3 mg/kg) significantly increased PR-ir levels
compared with vehicle treatment. B, MPN. PPT treatment (all doses)
and EB treatment significantly increased levels of PR-ir compared
with vehicle treatment. PR-ir levels did not differ between EB and
PPT treatments at any dose. *, Significantly different from vehicle
(P  0.001); , significantly different from EB (P  0.05).
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and PR expression is virtually absent (Fig. 4B). EB treatment
dramatically alters PR-ir in the MPN but does little to PR-ir
in the VMNvl. The ability of EB treatment to induce PR-ir in
these regions coincides with the differential expression of
ER in MPN and VMN.
Discussion
The present results implicate ER as an inhibitor of ER
transcriptional activity in the brain, representing a cellular
level function for ER in vivo. Selective activation of ER
by PPT, in the relative absence of ER activation, induced
PR expression in the neonatal VMN to a greater extent than
estradiol, which similarly activates both ER and ER. The
PPT-induced increase was attenuated when ER was ac-
tivated with the selective agonist, DPN. These results sug-
gest that activation of ER by estradiol in the VMN inhibits
ER transcriptional activity, thereby suppressing ER-me-
diated transactivation of the PR gene in this brain region.
The inhibition of ER transcriptional activity by ER was
specific to the VMN, which expresses both ER and ER.
In the MPN, an area that expresses high levels of ER
but very low levels of ER (28), PR was equally induced
by EB and PPT, and the ER agonist DPN had no effect,
indicating an absence of an ER/ER interaction in this
region. These data implicate ER in the anatomically
and developmentally specific effects of estradiol in the
brain.
Estradiol can dramatically influence brain development as
clearly demonstrated in the sexual differentiation of the ro-






















































FIG. 2. Selective activation of ER attenuates the induction of PR ex-
pression by ER in the VMN, but not the MPN. The mean (SEM) total
amount of PR-ir within the VMNvl or the MPN of female rats on P7
treated with vehicle (n 11), EB (20 g/kg, n 8), or the ER selective
agonist, PPT (2 mg/kg, n  8) or PPT in combination with the ER
selective agonist, DPN, at 0.5, 3.5, or 5 mg/kg (n  10, 9, 7) on P5 and
P6.A,VMNvl.PR-ir levelsweresignificantlyhigherafterPPTtreatment
(2 mg/kg) compared with EB treatment. The effect of PPT was signifi-
cantly attenuated by the addition of DPN at all doses. PR-ir was sig-
nificantlyhigher inall treatmentgroupscomparedwithvehicle.B,MPN.
PPT treatment alone, or PPT in combination with any dose of DPN, did
not significantly alter PR-ir levels compared with EB treatment. PR-ir
was significantly higher in all treatment groups compared with vehicle.
*, Significantly different from vehicle (P  0.001); , significantly dif-
ferent fromEB (P 0.01); #, significantly different fromPPT (3.5mg/kg













































FIG. 3. DPNalone does not activateER in theMPN. Themean (SEM)
total amount of PR-ir within the VMNvl or the MPN of female rats
on P7 treated with vehicle (n  11), or DPN at 3.5 mg/kg (n  10) on
P5andP6.A,VMNvl. PR-ir levelswere significantly higher afterDPN
treatment compared with vehicle. B, MPN. DPN treatment had no
significant (n.s.) effect on PR-ir. *, Significantly different from vehicle
(P  0.05).
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anatomically specific, such that estradiol can exert strong
effects in one area of the brain, whereas having little to no
influence in other areas despite ample ER expression (41,
42). For example, in the neonatal female rat brain, PR ex-
pression is increased 50-fold within the MPN after a single
injection of estradiol 48 h before tissue collection (25). In stark
contrast, PR expression is not altered in the VMNof the same
animals and only becomes more responsive to estradiol later
in postnatal development. Here, we demonstrate a potential
mechanism underlying the regional specificity of estradiol
action in developing brain.
TreatmentwithDPNalone (at themost effective dose from
experiment 2) had no effect on PR-ir in the MPN in which
ER expression is very low, demonstrating that this dose of
DPNwas selective for ER and did not significantly activate
ER. Interestingly, DPN alone increased PR levels slightly
within the ER-rich VMN of the same animals. This may be
explained by findings from in vitro studies demonstrating
that ER, in the absence of ER activity, can form ho-
modimers capable of weakly inducing the transcription of
ER-driven reporter genes (7, 43–45). The present findings
also document doses of PPT and DPN that when combined,
mimic the effect of estradiol in our paradigm. It is noteworthy
that DPN at the highest dose had a diminished inhibitory
effect on PR-ir levels compared with lower doses in exper-
iment 2. This is most likely due to the activation of ER by
high levels of DPN. Furthermore, we noticed a similar effect
with the highest dose of PPT in experiment 1, suggesting that
at high doses, the selectivity of these agonists may be di-
minished in vivo.
The differential regulation of estradiol signaling in the
MPN and VMN can be attributed to the differential ex-
pression of ER, and may be essential for the proper de-
velopment of these two reproductively important brain
regions as previously reported (36, 37, 39). The VMN is
important for successful mating behavior in females (46,
47), whereas the MPN is essential for the complex reper-
toire of maternal behaviors after parturition (48). The
present results are consistent with the idea that interac-
tions between ER and ER within the developing VMN
may be critical to protect the VMN from defeminization by
estradiol during important periods of development, thus
ensuring proper feminization of the VMN and subsequent
adult female sexual behavior.
Results from Kudwa et al. (22) support this hypothesis
by demonstrating that selective activation of ER or ER
during development alters female sexual behavior in
adulthood.
Additional work demonstrates that a role for ER is not
exclusive to sexual behavior but, rather, may mediate nu-
merous neurological functions. ER has been implicated in
modulating behaviors such as spatial ability (21), anxiety
(49, 50), and aggression [(51), and see Ref. 52 for an ex-
tensive review]. Furthermore, Bodo et al. (34) have sug-
gested that ER may be mediating the effects of estradiol
through interactions with ER. For example, Imwalle et al.
(50) have demonstrated that ER knockout (KO)mice have
higher anxiety levels compared with ER KO females and
wild-type mice, suggesting that ER may modulate the
effects of estradiol through antagonistic effects on ER
activity. In addition, the ability of estradiol to induce PR
expression in the medial preoptic area of adult ER KO
and ER KO mice and ERKO mice suggests that ER
and ER interact in complex ways to regulate the brain and
behavior (27). Our results are consistent with many of
these observations and provide a possible model to study
the cellular mechanisms underlying the modulation of
ER by ER within the brain.
The present results elucidating a novel role for ER in vivo
are consistent with in vitro work reporting that ER inhibits
the transcriptional activity of ER by direct physical inter-
actions between the two receptors, (i.e. heterodimerization
and/or cofactor recruitment) (16, 17, 19). Present findings
strongly suggest that ER, ER, and PR are expressedwithin
overlapping cell populations within the VMN, but not the
MPN, creating the possibility that ER and ER could have
direct interactions with one another in PR expressing cells.
However, the intriguing possibility also exists that indirect,
transsynaptic regulation of ER activity by ER occurs in the
developing brain. In vitro studies (17) aswell as in vivo studies
in adult brain (53, 54) demonstrate that estradiol increases the
transcription of the PR gene. Therefore, changes in PR-ir
levels in the present study are likely attributable to changes
in transcription of the PR gene, but the possibility also exits
that alterations in translation or turnover rate of PR protein
may also occur within the developing brain.
The present studies elucidate mechanisms underlying es-
trogen signaling in brain, which becomes an increasingly
important issue as the clinical use of estrogens and SERMs




FIG. 4. Differential ER expression coincides with the abil-
ity of estradiol to induce PR in the VMN and MPN. ER,
ER, and PR immunoreactive nuclei within (A) the VMNvl
or (B) the MPN of P7 female rats. PR-ir is shown in females
treated with vehicle or with EB (20 g/kg) on P5 and P6.
Magnification bars, 100 m.
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increases. The present results implicate ER in the inhibition
of ER transcriptional activity in the anatomically and de-
velopmentally specific actions of estradiol within the devel-
oping brain. Furthermore, we introduce the neonatal female
VMN as a powerful in vivo model in which to study the
mechanisms by which specificity of steroid-induced gene
expression is achieved.
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